Discover and read the best of Twitter Threads about #justpublished

#JustPublished!
Autumn #vaccination campaigns focused on older age groups and other high-risk populations are key to decrease impact of #COVID19.

Read full report: bit.ly/3ZJgEWk
Press release: bit.ly/3MdQjwJ

To decrease the impact of #COVID19 hospitalisations and mortality, countries should plan for a continued roll-out of #COVID19vaccines.

Efforts should focus on protecting older adults & other vulnerable groups, such as those with underlying comorbidities & the immunocompromised.

According to #ECDC surveillance data, with every new wave of #COVID19 infection, individuals in older age groups are more likely to be hospitalised.

Data suggests persisting #SARSCoV2 transmission in EU/EEA & therefore, a continuous risk of severe disease for vulnerable groups.

Read 8 tweets

ECDC

#JustPublished!
Threat Assessment Brief: Implications for the EU/EEA of the spread of the #SARSCoV2 #Omicron XBB.1.5 sub-lineage.

Overall level of risk is low for the EU/EEA general population; moderate to high for vulnerable individuals.

Read:
bit.ly/XBB15TAB
#COVID19

Mathematical modelling indicates that #XBB15 could become dominant in the EU/EEA after 1-2 months, given the current low proportions reported in the EU/EEA & its estimated growth rate.

No signals of increased severity of XBB.1.5 compared to circulating omicron sub-lineages.

The proportion of XBB.1.5 in EU/EEA was lower than 2.5% for the final 2 weeks of '22 (the most recent period where variant proportions at this low level can be accurately estimated).

In the US, #XBB15 is currently spreading 12% faster than other variants.
bit.ly/XBB15TAB

ECDC

#JustPublished!
Increase in Invasive Group A streptococcal infections among children in Europe, including fatalities .

Full press release:
ecdc.europa.eu/en/news-events…

#StrepA #iGAS

A number of European countries (IE, FR, NL, ES, SE and UK) indicate an increase seen during 2022, particularly since September, in the number of cases of invasive Group A Streptococcus (#iGAS) disease among children less than ten years of age.

#StrepA

During the same period, several deaths associated with #iGAS in children less than 10 years of age have also been reported. The increase has been several-fold higher than pre-pandemic levels for the equivalent period of time. 

Read more:
ecdc.europa.eu/en/news-events…

#StrepA

Read 5 tweets

#JustPublished!
Spread of the #SARSCoV2 #Omicron variant sub-lineage BQ.1 in the EU/EEA.

BQ.1, including its sub-lineages, has been designated as Variant of Interest (#VOI) by ECDC as of 20 October 2022.

Full report: bit.ly/3VMLay0

Based on modelling estimates, it is expected that by mid-November to beginning of December 2022, more than 50% of #SARSCoV2 infections will be due to BQ.1/BQ.1.1.

That level is expected to rise by the beginning of 2023, to more than 80%.

bit.ly/3VMLay0
#Omicron #BQ1

The observed increase in the growth rate of BQ.1 is probably driven mainly by immune escape.

This variant and its sub-lineages will probably contribute to a further increase in cases of #COVID19 in the EU/EEA in the coming weeks and months.

#Omicron #BQ1

Read 7 tweets

Pandora Patterson

@PPattersonPhD

@NatalieKB8

[1/3] What happens to AYA cancer survivors' wellbeing over time? Our new paper #justpublished reviews longitudinal studies to better understand these outcomes & help AYAs reach their full potential in life 💪 @NatalieKB8 @CanteenAus #AYAcancer onlinelibrary.wiley.com/doi/10.1002/po…

[2/3] Longitudinal studies are important for understanding how outcomes change over time. This global review identifies a wide range of outcomes important to AYA cancer survivors that have been studied longitudinally 👇 onlinelibrary.wiley.com/doi/10.1002/po…

[3/3] Some studies found improvements over time, others identified very little progress for a significant number of AYAs, indicating need for greater understanding & intervention 👇onlinelibrary.wiley.com/doi/10.1002/po…

Read 3 tweets

ECDC

@EMA_News

#JustPublished!
@EMA_News and @ECDC_EU recommendations on "mix and match" vaccination courses and boosters.

Read full text here: bit.ly/3pDe6tb

Vaccines are continuing to prevent many millions of EU citizens from becoming very ill or dying and figures show that numbers of hospitalisations and deaths remain lowest in those Member States with the highest vaccination rates.

#COVID19 #VaccinesSaveLives #VaccinesWork

Due to a raise in #COVID19 infections and hospitalisations, we urge all EU citizens to get fully vaccinated and to adhere to recent recommendations on booster vaccination for #COVID19.

Recommendations on booster doses in our latest Rapid Risk Assessment: bit.ly/RRACOVID17

ECDC

#JustPublished!
Interim public health considerations for the provision of additional #COVID19 vaccine doses.

Read full report here: bit.ly/ECDCBoosterDoc

Providing all eligible individuals with the recommended dose regimen should remain the current
priority for #COVID19 vaccination programmes in the EU/EEA.

All vaccines authorised in the EU/EEA are highly protective against COVID19 related hospitalisation, severe disease & death.

Administering an additional vaccine dose to people who may experience a limited response to the primary #COVID19 vaccination, such as some categories
of immunocompromised individuals, should already be considered now.

bit.ly/ECDCBoosterDoc

Read 5 tweets

@EFSA_EU

#JustPublished:

Joint #ECDC, @EFSA_EU and #EURL Lm report: European Listeria typing exercise (ELiTE).

A cross-sectorial study identifies strong link between human #listeriosis clusters and ready-to-eat fish products.

Full text: bit.ly/3d5XzYn

#Listeriosis is a foodborne disease caused by L. monocytogenes bacteria. After ingestion via contaminated food, it can cause severe, life-threatening disease, often manifested as #septicaemia and/or #meningitis.

The severe disease happens particularly among elderly & immunocompromised people. It also may result in complications related to pregnancy.

ecdc.europa.eu/en/news-events…

#JustPublished:
Considerations on the use of #COVID19 self-tests in the EU/EEA.

Full text: bit.ly/30UZx8h

Rapid antigen detection tests (#RADTs) that can be used as self-tests to detect #SARSCoV2 are becoming increasingly available on the EU/EEA markets.

These tests require individuals to collect a specimen, conduct a test and interpret the results by themselves.

At the time of writing this document, there were only a few #RADTs available for self-testing, and there was none CE-marked on the EU market in compliance with Directive 98/79/EC.